Valuation: Intervacc AB

Market Cap 346M 34.62M 30.49M 28.88M 26.08M 49.15M 3.32B 49.78M 133M 1.7B 130M 127M 5.44B P/E 2026 *
-0.91x
P/E 2027 * -0.91x
Enterprise Value 257M 25.7M 22.63M 21.45M 19.36M 36.49M 2.46B 36.96M 98.74M 1.26B 96.52M 94.41M 4.04B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 9.49x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day+2.42%
1 week+4.54%
1 month-4.34%
3 months-22.24%
6 months+23.06%
Current year+9.74%
1 week 0.94
Extreme 0.935
1.04
1 month 0.9
Extreme 0.9
1.14
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/23/25 Free

Chief Financial Officer

929,208 1.2269%
2/17/25 Buy

Chief Executive Officer

135,000 0.1783%
2/17/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%+4.54%-2.50%-71.27% 34.62M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.19%+1.32%+37.20%+83.85% 60.14B
-1.51%+2.39%+9.10%+35.15% 48.15B
-0.05%+0.37%+41.54%+36.65% 44.25B
+0.38%+7.61%+339.53%+641.55% 43.99B
+0.18%+0.26%+7.41%+103.45% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.29%-3.55%-20.74%+352.04% 24.93B
Average +0.82%+1.83%+50.53%+134.47% 39.68B
Weighted average by Cap. +0.84%+1.53%+61.04%+147.99%

Financials

2026 *2027 *
Net sales 21M 2.1M 1.85M 1.76M 1.58M 2.99M 202M 3.03M 8.08M 103M 7.9M 7.73M 331M 30M 3.01M 2.65M 2.51M 2.26M 4.27M 288M 4.32M 11.54M 147M 11.28M 11.04M 472M
Net income -82.45M -8.26M -7.27M -6.89M -6.22M -11.73M -792M -11.88M -31.73M -405M -31.01M -30.34M -1.3B -83.65M -8.38M -7.38M -6.99M -6.31M -11.9M -803M -12.05M -32.19M -411M -31.47M -30.78M -1.32B
Net Debt -89M -8.92M -7.85M -7.44M -6.72M -12.66M -855M -12.82M -34.25M -437M -33.48M -32.75M -1.4B -61M -6.11M -5.38M -5.1M -4.6M -8.68M -586M -8.79M -23.47M -300M -22.95M -22.45M -960M
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-09-30 SEK 1.014 +2.42% 309,182
26-09-29 SEK 0.9900 +5.88% 484,605
26-09-28 SEK 0.9350 -2.40% 309,588
26-09-25 SEK 0.9580 -0.10% 152,817
26-09-24 SEK 0.9590 -1.13% 352,606

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock